

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-10 (previously canceled)

Claim 11 (canceled)

Claim 12 (canceled)

Claims 13-26 (previously canceled)

Claim 27 (currently amended): A pharmaceutical agent for therapy of rheumatism, characterized in that said pharmaceutical agent contains a compound selected from 2-(3,4-dihydroxy-1-butenyl)-4-(2-formylvinyl)-1,3-dioxolane, and 4(9-guaninyl)-2-cyclopenten-1-one as the effective

Claim 28 (previously cancelled)

Claim 29 (previously cancelled)

Claim 30 (new): A compound selected from


4-(9-adeninyl)-2-cyclopenten-1-one,

4-(9-guaninyl)-2-cyclopenten-1-one,

1,5-epoxy-1-hydroxy-3-penten-2-one,


2-(3,4-dihydroxy-1-butenyl)-4-(2-formylvinyl)-1,3-dioxolane, and

the compound represented by the following formula [II]



Claim 31 (new): A pharmaceutical agent characterized in that said pharmaceutical agent contains a compound selected from

4-(9-adeninyl)-2-cyclopenten-1-one,
4-(9-guaninyl)-2-cyclopenten-1-one,
2-(3,4-dihydroxy-1-butenyl)-4-(2-formylvinyl)-1,3-dioxolane,
1,5-epoxy-1-hydroxy-3-penten-2-one, and
a compound represented by the formula [II] as an effective component



a pharmaceutical carrier.